Long-term results of Nivolumab + Cabozantinib in RCC

Published Date: 08 Mar 2023

The combination of first-line nivolumab and cabozantinib continues to outperform sunitinib in the treatment of patients with advanced renal cell carcinoma (RCC).

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

A video animation guide to assist young people who are fatigued from cancer.

2.

Cabozantinib Improves PFS for Advanced Neuroendocrine Tumors

3.

Aspirin Fails to Boost Survival in Colorectal Cancer Trial

4.

AI Framework Helps Classify Renal Tumors, Predict Outcomes

5.

NEJM: Pirtobrutinib is effective in CLL patients who have received prior BTK inhibitor therapy.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot